文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

COVID-19 疫苗接种后免疫抑制性疾病患者的 SARS-CoV-2 特异性免疫反应和临床结局。

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

机构信息

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

出版信息

Nat Med. 2023 Jul;29(7):1760-1774. doi: 10.1038/s41591-023-02414-4. Epub 2023 Jul 6.

DOI:10.1038/s41591-023-02414-4
PMID:37414897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10353927/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (<380 AU ml). Vaccine failure rates were highest in ANCA-associated vasculitis on rituximab (21/29, 72%), hemodialysis on immunosuppressive therapy (6/30, 20%) and solid organ transplant recipients (20/81, 25% and 141/458, 31%). SARS-CoV-2-specific T cell responses were detected in 513 of 580 (88%) patients, with lower T cell magnitude or proportion in hemodialysis, allogeneic hematopoietic stem cell transplantation and liver transplant recipients (versus healthy controls). Humoral responses against Omicron (BA.1) were reduced, although cross-reactive T cell responses were sustained in all participants for whom these data were available. BNT162b2 was associated with higher antibody but lower cellular responses compared to ChAdOx1 nCoV-19 vaccination. We report 474 SARS-CoV-2 infection episodes, including 48 individuals with hospitalization or death from COVID-19. Decreased magnitude of both the serological and the T cell response was associated with severe COVID-19. Overall, we identified clinical phenotypes that may benefit from targeted COVID-19 therapeutic strategies.

摘要

评估了 2686 名患有不同免疫抑制性疾病的患者在接种两种 2019 年冠状病毒病（COVID-19）疫苗后的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）免疫反应和感染结果。总体而言，2204 名患者中有 255 名（12%）未能产生抗刺突抗体，另外 2204 名患者中有 600 名（27%）产生低水平抗体（<380 AU/ml）。在利妥昔单抗治疗的抗中性粒细胞胞质抗体相关性血管炎（21/29，72%）、免疫抑制治疗的血液透析（6/30，20%）和实体器官移植受者中，疫苗失败率最高（20/81，25%和 141/458，31%）。在 580 名患者中的 513 名（88%）患者中检测到 SARS-CoV-2 特异性 T 细胞反应，与健康对照组相比，血液透析、异基因造血干细胞移植和肝移植受者的 T 细胞数量或比例较低。针对奥密克戎（BA.1）的体液反应降低，尽管对于所有有这些数据的参与者，交叉反应性 T 细胞反应仍然持续。与 ChAdOx1 nCoV-19 疫苗相比，BNT162b2 接种后抗体水平较高，但细胞反应较低。我们报告了 474 例 SARS-CoV-2 感染病例，包括 48 例因 COVID-19 住院或死亡的患者。血清学和 T 细胞反应幅度的降低与严重 COVID-19 相关。总的来说，我们确定了可能受益于靶向 COVID-19 治疗策略的临床表型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/d5aace766ece/41591_2023_2414_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/e45a12b77565/41591_2023_2414_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/898d95380485/41591_2023_2414_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/50facc5a1956/41591_2023_2414_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/6f3daee47c08/41591_2023_2414_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/99451c4558ee/41591_2023_2414_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/768926fe6789/41591_2023_2414_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/ff7d78369a3c/41591_2023_2414_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/55dbb713e048/41591_2023_2414_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/af8df0387470/41591_2023_2414_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/af939be68dd8/41591_2023_2414_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/7f788a3dfbe6/41591_2023_2414_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/00910ca7d323/41591_2023_2414_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/d5aace766ece/41591_2023_2414_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/e45a12b77565/41591_2023_2414_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/898d95380485/41591_2023_2414_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/50facc5a1956/41591_2023_2414_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/6f3daee47c08/41591_2023_2414_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/99451c4558ee/41591_2023_2414_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/768926fe6789/41591_2023_2414_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/ff7d78369a3c/41591_2023_2414_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/55dbb713e048/41591_2023_2414_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/af8df0387470/41591_2023_2414_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/af939be68dd8/41591_2023_2414_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/7f788a3dfbe6/41591_2023_2414_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/00910ca7d323/41591_2023_2414_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df92/10353927/d5aace766ece/41591_2023_2414_Fig13_ESM.jpg

相似文献

[1]
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

Nat Med. 2023-7

[2]
Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.

Microbiol Spectr. 2021-12-22

[3]
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.

Lancet Healthy Longev. 2021-9

[4]
Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis.

Lancet Healthy Longev. 2021-9

[5]
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.

Allergy. 2022-8

[6]
Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.

Microbiol Spectr. 2022-8-31

[7]
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Lancet. 2020-7-20

[8]
Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.

Br J Haematol. 2022-8

[9]
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.

Lancet Infect Dis. 2022-4

[10]
mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.

J Virol. 2025-3-18

引用本文的文献

[1]
The Impact of the COVID-19 Pandemic on an Immunocompromised Patient with Allogeneic Haematopoietic Stem Cell Transplant: A Dual Perspective from Patient and Physician Standpoints.

Oncol Ther. 2025-8-25

[2]
Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients.

Cells. 2025-7-26

[3]
XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease.

Vaccines (Basel). 2025-7-16

[4]
A Randomized Trial of At-Home COVID-19 Tests, Telemedicine, and Rapid Prescription Delivery for Immunocompromised Individuals.

Mayo Clin Proc Innov Qual Outcomes. 2025-5-22

[5]
Advances in the treatment of ANCA-associated vasculitis.

Nat Rev Rheumatol. 2025-6-5

[6]
Early de novo T cell expansion following SARS-CoV-2 infection predicts favourable clinical and virological outcomes.

EBioMedicine. 2025-6-4

[7]
Features influencing the health and economic impact of preventing COVID-19 in immunocompromised individuals.

PLoS Comput Biol. 2025-6-2

[8]
The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles.

EClinicalMedicine. 2025-5-5

[9]
Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals.

Microorganisms. 2025-5-6

[10]
Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B.

PLoS One. 2025-5-23

本文引用的文献

[1]
Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.

Cell Rep Med. 2022-12-20

[2]
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.

Lancet. 2022-10-15

[3]
Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience.

Front Immunol. 2022

[4]
Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity.

Nat Commun. 2022-9-21

[5]
Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study.

Lancet Reg Health Eur. 2022-10

[6]
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.

Nat Commun. 2022-8-11

[7]
Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study.

BMJ. 2022-8-2

[8]
Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study.

Ann Rheum Dis. 2022-11

[9]
Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.

PLoS Med. 2022-5

[10]
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.

Lancet Infect Dis. 2022-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索